Therapeutic strategies to prevent motor complications in Parkinson’s disease
- 163 Downloads
Dopaminergic treatment of Parkinson’s disease (PD) leads to significant improvement in Parkinsonian features; however, the treatment response is hampered by the appearance of motor complications, including dyskinesias and motor fluctuations. These motor complications have a significant negative impact on quality-of-life. Therapeutic strategies using different types and timing of dopaminergic therapy may influence the emergence of motor complications. While sustained release preparations of levodopa have not shown benefit over immediate release preparations, the early combination of a dopamine agonist with levodopa appears to reduce the onset of motor fluctuations. An even larger body of evidence has found that initiating treatment with a dopamine receptor agonist (as compared to immediate release levodopa) is associated with a reduction in motor fluctuations, particularly dyskinesias. These data have led to evidence-based medicine evaluations indicting that the use of dopamine agonists is efficacious and clinically useful for the prevention of motor complications.
Key wordsParkinson’s disease Motor complications Dyskenias Dopamine agonists Levodopa
Unable to display preview. Download preview PDF.
- 3.Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K, CALMPD Investigators of the Parkinson Study Group (2007) Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord online in Wiley InterScience (www.interscience.wiley.com). DOI:10.1002/mds.21292Google Scholar
- 5.Efficacy and safety of carbiodopa/levodopa/entacapone in patients with Parkinson’s disease requiring initiation of levodopa therapy. Clinical Trials. Government Identifier NCT00099268Google Scholar
- 6.Giménez-Roldán S, Tolosa E, Burguera JA, Chacón J, Liano, Forcadell F (1997) Early combination of bromocriptine and levodopa in Parkinson’s disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharm 20:67–76CrossRefGoogle Scholar
- 11.Parkinson Study Group (2000) Pramipexole vs. levodopa as initial treatment for Parkinson disease. A randomized controlled trial. JAMA 284:1931–1938Google Scholar